Management of hyperlipidaemia

Drug and Therapeutics Bulletin

Volumn 34, Issue 12, 1996, Pages 89-93

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; COLESTIPOL; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ANOREXIA; ARTICLE; CONSTIPATION; CORONARY RISK; DIARRHEA; DIET THERAPY; HEADACHE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; NAUSEA; PRURITUS; RASH;

EID: 0030476838     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1996.341289     Document Type: Article

References (38)

1. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Principal results. Heart 1996; 75: 334-42.
2. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986; ii: 933-6.
3. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-81.
4. Pekkanen J, Linn S, Heiss PHG et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-7.
5. Women and coronary heart disease. DTB 1996; 34: 28-30.
6. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
7. Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-8.
8. Kannel WB, Wilson PWF. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992; 124: 768-74.
9. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-56.
10. Neil HAW, Roe L, Godlee RJP et al. Randomised mal of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ 1995; 310: 569-73.
11. Schaefer EJ, Lichtenstein AH, Lamon-Fava S et al. Efficacy of a National Cholesterol Education Program Step 2 Diet in normolipidemic and hypercholesterolemic middle-aged and elderly men and women. Arterioscler Thromb Vasc Biol 1995; 15: 1079-85.
12. Choudhury S, Jackson P, Katan MB et al. A multifactorial diet in the management of hyperlipidaemia. Atherosclerosis 1984; 50: 93-103.
13. Katzel LI, Bleecker ER, Colman EG, Rogus EM, Sorkin JD, Goldberg AP. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controlled trial. JAMA 1995; 274: 1915-21.
14. Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991; 325: 461-6.
15. Illingworfh DR, Erkelens DW, Keller U, Thompson GR, Tikkanan MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994; 343: 1554-5.
16. Schulte K-L, Beil S. Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolaemic patients. A double-blind, randomised, parallel-group comparison. Clin Drug Invest 1996; 12: 119-26.
17. Pan HY, DeVault AR, Swites BJ et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990; 48: 201-7.
18. Rhabdomyolysis associated with lipid-lowering drugs.Curr Prob Pharmacovigil 1995; 21: 3.
19. Management of hyperlipidaemia. DTB 1987; 25: 89-92.
20. Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990; 40: 260-90.
21. O'Brien RC, Simons LA, Clifton P et al. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Med J Aust 1990; 152: 480-3.
22. Superko HR, Greenland P, Manchester RA et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cordial 1992; 70: 135-40.
23. Acipimox - a nicotinic acid analogue for hyperlipidaemia. DTB 1991; 29: 57-9.
24. Schectman G, Hiatt J, Hartz A. Evaluation of effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol 1993; 71: 759-65.
25. Increasing fish oil intake - any net benefits? DTB 1996; 34: 60-2.
26. Schmidt EB, Kristensen SD, De Caterina R, Illingworth RD. The effects of n-3 fatty acids on plasma lipids and lipoproteins and other cardiovascular risk factors in patients wit hhyperlipidemia. Atherosclerosis 1993; 103: 107-21.
27. Thompson GR. Angiographic trials of lipid-lowering therapy: end of an era? Br Heart J 1995; 74: 343-7.
28. Thompson GR, Hollyer J, Waters DD.Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995; 6: 386-8.
29. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-73.
30. Shepherd J, Cobbe SM, Ford I et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
31. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
32. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274-5.
33. Pedersen TR, Kjekshus J, Berg K et al for the Scandinavian Simvastatin Survival Study. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-802.
34. Sacks FM, Pfeffer MA, Moye LA et al for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
35. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin CM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.Lancet 1996; 348: 387-8.
36. Ramsay LE, Haq IU, Jackson PR, Yeo WW. The Sheffield table for primary prevention of coronary heart disease: corrected. Lancet 1996; 348: 1251-2 [letter].
37. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443-8.
38. Haq IU, Ramsey LE, Pickin DM, Yeo WW, Jackson PR, Payne. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci 1996; 91: 399-413.